-
公开(公告)号:EP4448580A2
公开(公告)日:2024-10-23
申请号:EP22908303.5
申请日:2022-12-13
-
2.
-
公开(公告)号:EP4416808A1
公开(公告)日:2024-08-21
申请号:EP22881524.7
申请日:2022-08-12
CPC分类号: F16L7/00 , H02G1/088 , G02B6/502 , G02B6/504 , G02B6/4457
-
公开(公告)号:EP4324918A3
公开(公告)日:2024-04-24
申请号:EP23215391.6
申请日:2014-08-22
IPC分类号: C12N15/39 , A61K39/285 , A61K35/768 , C12N7/00
CPC分类号: C12N2710/2413220130101 , A61K39/12 , A61K2039/525620130101 , A61K2039/57220130101 , A61K2039/58520130101 , C12N2710/2412120130101 , C12N2710/2413420130101 , A61K2039/57520130101 , A61P35/00 , A61P35/02
摘要: The present invention relates to oncolytic vaccinia viruses which have been modified to promote anti-tumor immunity and/or reduce host immunity and/or antibody response against the virus. It is based, at least in part, on the discovery that oncolytic vaccinia virus (i) bearing a genome deletion of a gene that reduces T cell immunity (interleukin-18 binding protein); (ii) treated with a sialidase enzyme which is believed to reduce TLR2 activation and therefore the antibody response; (iii) carrying a gene that enhances cytotoxic T lymphocyte induction (e.g., TRIF) and/or (iv) reduces tumor myeloid-derived suppressor cells by reducing prostaglandin E2 reduces tumor growth. Accordingly, the present invention provides for immunooncolytic vaccinia viruses and methods of using them in the treatment of cancers.
-
公开(公告)号:EP4334339A2
公开(公告)日:2024-03-13
申请号:EP22799371.4
申请日:2022-05-02
申请人: University of Pittsburgh - of the Commonwealth System of Higher Education , Bluesphere Bio, Inc.
发明人: ITO, Sawa , SHLOMCHIK, Warren David , SHLOMCHIK, Mark Jay , PANOUSIS, Constantinos George , KIM, Josh , MARTIN, Erik , WIKENHEISER, Daniel
IPC分类号: C07K14/705
-
公开(公告)号:EP4333866A1
公开(公告)日:2024-03-13
申请号:EP22799710.3
申请日:2022-05-06
-
公开(公告)号:EP4305069A1
公开(公告)日:2024-01-17
申请号:EP22767820.8
申请日:2022-03-08
-
公开(公告)号:EP4294442A1
公开(公告)日:2023-12-27
申请号:EP22756786.4
申请日:2022-02-15
IPC分类号: A61K39/395 , C07K16/18 , C07K9/00 , A61P35/00
-
公开(公告)号:EP4252842A3
公开(公告)日:2023-10-25
申请号:EP23186922.3
申请日:2018-03-02
摘要: Methods are disclosed for inhibiting esophageal inflammation in a subject, that include administering to the esophagus of the subject with esophageal inflammation a therapeutically effective amount of an extracellular matrix (ECM) hydrogel. Methods are also disclosed for reducing esophageal stricture. Compositions are disclosed that include an esophageal extracellular matrix (ECM) hydrogel.
-
公开(公告)号:EP4257202A2
公开(公告)日:2023-10-11
申请号:EP23168344.2
申请日:2012-11-09
申请人: Trustees of Tufts College , University of Pittsburgh - Of the Commonwealth System of Higher Education , Wake Forest University Health Services
IPC分类号: A61P43/00
摘要: The inventions provided herein relate to compositions, methods, delivery devices and kits for repairing or augmenting a tissue in a subject. The compositions described herein are injectable such that they can be placed in a tissue to be treated with a minimally-invasive procedure (e.g., by injection) and/or be molded flexibly into a tissue void of any shape and/or size. In some embodiments, the composition described herein comprises a plurality of silk fibroin particles, which can retain their original volume within the tissue for a period of time. The compositions can be used as a filler to replace a tissue void, e.g., for tissue repair and/or augmentation, or as a scaffold to support tissue regeneration and/or reconstruction. In some embodiments, the compositions described herein can be used for soft tissue repair or augmentation.
-
-
-
-
-
-
-
-
-